First-in-man study of western reserve strain oncolytic vaccinia virus: Safety, systemic spread, and antitumor activity

Molecular Therapy

Volumn 23, Issue 1, 2015, Pages 202-214

  Zeh, Herbert J ^a   Downs Canner, Stephanie ^a   McCart, J Andrea ^b   Guo, Zong Sheng ^a   Rao, Uma N M ^c   Ramalingam, Lekshmi ^a   Thorne, Stephen H ^a   Jones, Heather L ^a   Kalinski, Pawel ^a   Wieckowski, Eva ^a   O'Malley, Mark E ^a   Daneshmand, Manijeh ^d   Hu, Kang ^d   Bell, John C ^d   Hwang, Tae Ho ^e,f   Moon, Anne ^f   Breitbach, Caroline J ^f   Kirn, David H ^f   Bartlett, David L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e Pusan National University   (South Korea)

^f SillaJen Inc   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; NARCOTIC ANALGESIC AGENT; ONCOLYTIC VIRUS;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASCITES; BACKACHE; BLOOD LEVEL; BLOOD TOXICITY; BODY WEIGHT DISORDER; BREAST CANCER; CANCER PATIENT; CECUM CANCER; CHILL; CLINICAL ARTICLE; COGNITIVE DEFECT; COLON CANCER; COLON TUMOR; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISTANT METASTASIS; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FLANK PAIN; GASTROINTESTINAL HEMORRHAGE; GENE DELETION; GENE TARGETING; GENOME ANALYSIS; HEARTBURN; HEMATOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; IMMUNE RESPONSE; INFLAMMATORY DISEASE; INJECTION SITE PAIN; INTERNATIONAL NORMALIZED RATIO; LEG EDEMA; LEUKOPENIA; LIVER TOXICITY; MALAISE; MALE; MAXIMUM PERMISSIBLE DOSE; MELANOMA; MIDDLE AGED; MYALGIA; ONCOLYTIC VIROTHERAPY; PAIN; PANCREAS CANCER; PANCREATITIS; PELVIC PAIN; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PROTHROMBIN TIME; PRURITUS; REPRODUCIBILITY; RESPIRATORY TRACT DISEASE; SOLID TUMOR; SYMPTOM; SYSTEMIC THERAPY; THORAX PAIN; TREATMENT RESPONSE; URINARY TRACT INFECTION; URINE RETENTION; VACCINIA VIRUS; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN; VOMITING; WEIGHT REDUCTION; ANIMAL; BREAST NEOPLASMS; CLINICAL TRIAL; COLONIC NEOPLASMS; DOSE RESPONSE; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INTRALESIONAL DRUG ADMINISTRATION; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; SKIN NEOPLASMS; TUMOR CELL LINE;

ANIMALIA; VACCINIA VIRUS;

AGED; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GENE DELETION; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MELANOMA; MIDDLE AGED; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PANCREATIC NEOPLASMS; SKIN NEOPLASMS; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 84920669908     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.194     Document Type: Article

References (35)

1. Martuza, RL, Malick, A, Markert, JM, Ruffner, KL and Coen, DM (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856.
2. Russell, SJ, Peng, KW and Bell, JC (2012). Oncolytic virotherapy. Nat Biotechnol 30: 658-670.
3. Guo, ZS, Thorne, SH and Bartlett, DL (2008). Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 1785: 217-231.
4. Kirn, D (2001). Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 8: 89-98.
5. Nemunaitis, J, Cunningham, C, Buchanan, A, Blackburn, A, Edelman, G, Maples, P et al. (2001). Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 8: 746-759.
6. Andtbacka, RHI, Collichio, FA, Amatruda, T, Senzer, NN, Chesney, J, Delman, KA et al. (2013). OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of unresected stage IIIB/C and IV melanoma. J Clin Oncol, ASCO Annual Meeting Abstracts. Vol. 31, No. 18-suppl (June 20 supplement), 2013: LBA9008.
7. Park, BH, Hwang, T, Liu, TC, Sze, DY, Kim, JS, Kwon, HC et al. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 9: 533-542.
8. Breitbach, CJ, Burke, J, Jonker, D, Stephenson, J, Haas, AR, Chow, LQ et al. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477: 99-102.
9. Heo, J, Reid, T, Ruo, L, Breitbach, CJ, Rose, S, Bloomston, M et al. (2013). Randomized dose-fnding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19: 329-336.
10. Tolonen, N, Doglio, L, Schleich, S and Krijnse Locker, J (2001). Vaccinia virus DNA replication occurs in endoplasmic reticulum-enclosed cytoplasmic mini-nuclei. Mol Biol Cell 12: 2031-2046.
11. Moss, B and Earl, PL (2002). Overview of the vaccinia virus expression system. Curr Protoc Mol Biol Chapter 16: Unit16.15.
12. Ichihashi, Y (1996). Extracellular enveloped vaccinia virus escapes neutralization. Virology 217: 478-485.
13. Vanderplasschen, A, Mathew, E, Hollinshead, M, Sim, RB and Smith, GL (1998). Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci USA 95: 7544-7549.
14. Roberts, KL and Smith, GL (2008). Vaccinia virus morphogenesis and dissemination. Trends Microbiol 16: 472-479.
15. Thorne, SH, Hwang, TH, O'Gorman, WE, Bartlett, DL, Sei, S, Kanji, F et al. (2007). Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 117: 3350-3358.
16. Puhlmann, M, Brown, CK, Gnant, M, Huang, J, Libutti, SK, Alexander, HR et al. (2000). Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 7: 66-73.
17. McCart, JA, Ward, JM, Lee, J, Hu, Y, Alexander, HR, Libutti, SK et al. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61: 8751-8757.
18. Naik, AM, Chalikonda, S, McCart, JA, Xu, H, Guo, ZS, Langham, G et al. (2006). Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates. Hum Gene Ther 17: 31-45.
19. Parato, KA, Breitbach, CJ, Le Boeuf, F, Wang, J, Storbeck, C, Ilkow, C et al. (2012). The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 20: 749-758.
20. Chalikonda, S, Kivlen, MH, O'Malley, ME, Eric Dong, XD, McCart, JA, Gorry, MC et al. (2008). Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther 15: 115-125.
21. Chang, E, Chalikonda, S, Friedl, J, Xu, H, Phan, GQ, Marincola, FM et al. (2005). Targeting vaccinia to solid tumors with local hyperthermia. Hum Gene Ther 16: 435-444.
22. Gnant, MF, Puhlmann, M, Bartlett, DL and Alexander, HR Jr (1999). Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases. Ann Surg 230: 352-60; discussion 360.
23. Sanderson, CM, Parkinson, JE, Hollinshead, M and Smith, GL (1996). Overexpression of the vaccinia virus A38L integral membrane protein promotes Ca2+ infux into infected cells. J Virol 70: 905-914.
24. Aragón, TJ, Ulrich, S, Fernyak, S and Rutherford, GW (2003). Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963-1968. BMC Public Health 3: 26.
25. Bartlett, DL, Liu, Z, Sathaiah, M, Ravindranathan, R, Guo, Z, He, Y et al. (2013). Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 12: 103.
26. Guo, ZS, Parimi, V, O'Malley, ME, Thirunavukarasu, P, Sathaiah, M, Austin, F et al. (2010). The combination of immunosuppression and carrier cells signifcantly enhances the effcacy of oncolytic poxvirus in the pre-immunized host. Gene Ther 17: 1465-1475.
27. Weibel, S, Raab, V, Yu, YA, Worschech, A, Wang, E, Marincola, FM et al. (2011). Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer 11: 68.
28. Ikeda, K, Ichikawa, T, Wakimoto, H, Silver, JS, Deisboeck, TS, Finkelstein, D et al. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 5: 881-887.
29. Thomas, MA, Spencer, JF, Toth, K, Sagartz, JE, Phillips, NJ and Wold, WS (2008). Immunosuppression enhances oncolytic adenovirus replication and antitumor effcacy in the Syrian hamster model. Mol Ther 16: 1665-1673.
30. Hasegawa, N, Abei, M, Yokoyama, KK, Fukuda, K, Seo, E, Kawashima, R et al. (2013). Cyclophosphamide enhances antitumor effcacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters. Int J Cancer 133: 1479-1488.
31. Thirunavukarasu, P, Sathaiah, M, Gorry, MC, O'Malley, ME, Ravindranathan, R, Austin, F et al. (2013). A rationally designed A34R mutant oncolytic poxvirus: improved effcacy in peritoneal carcinomatosis. Mol Ther 21: 1024-1033.
32. McCart, JA, Mehta, N, Scollard, D, Reilly, RM, Carrasquillo, JA, Tang, N et al. (2004). Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther 10: 553-561.
33. Kulesh, DA, Baker, RO, Loveless, BM, Norwood, D, Zwiers, SH, Mucker, E et al. (2004). Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms. J Clin Microbiol 42: 601-609.
34. Muthuswamy, R, Berk, E, Junecko, BF, Zeh, HJ, Zureikat, AH, Normolle, D et al. (2012). NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res 72: 3735-3743.
35. Schulz, KR, Danna, EA, Krutzik, PO and Nolan, GP (2007). Single-cell phospho-protein analysis by fow cytometry. Curr Protoc Immunol Chapter 8: Unit 8.17.